{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:00:31Z","timestamp":1785830431153,"version":"3.56.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Neuromuscular blocking agents (NMBAs) are primarily used during surgical procedures to facilitate endotracheal intubation and optimize surgical conditions. This study aimed to explore the adverse event signals of NMBAs, providing reference for clinical safety.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This study collected reports of atracurium, cisatracurium, rocuronium, and vecuronium as primary suspect drugs in The US Food and Drug Administration Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the third quarter of 2023. The adverse events (AEs) reported in the study were retrieved based on the Preferred Terms (PTs) of the Medical Dictionary for Regulatory Activities. In addition, we conducted disproportionality analysis on relevant reports using the reporting odds ratio (ROR) method and Bayesian confidence propagation neural network (BCPNN) method. A positive signal was generated when both algorithms show an association between the target drug and the AE.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 11,518 NMBA-related AEs were reported in the FAERS database. The most AEs of rocuronium were collected. NMBA-related AEs involved 27 different system organs (SOCs), all of the four NMBAs had positive signals in \u201ccardiac disorders,\u201d \u201cimmune system disorders,\u201d \u201crespiratory, thoracic and mediastinal disorders\u201d and \u201cvascular disorders.\u201d At the PTs level, a total of 523 effective AEs signals were obtained for the four NMBAs. AEs labled in the instructions such as anaphylaxis (include anaphylactic reaction and anaphylactic shock), bronchospasm, respiratory arrest and hypotension were detected positive signals among all NMBAs. In addition, we also found some new AEs, such as ventricular fibrillation for the four NMBAs, hyperglycaemia for atracurium, kounis syndrome and stress cardiomyopathy for rocuronium, hepatocellular injury for cisatracurium, hyperkalaemia for vecuronium. To further investigated the AEs associated with serious clinical outcomes, we found that cardiac arrest and anaphylaxis were the important risk factors for death due to NMBAs.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> NMBA-related AEs have a significant potential to cause clinically severe consequences. Our study provides valuable references for the safety profile of NMBAs, and considering the limitations of the FAERS database, further clinical data are needed to validate the findings of this study.<\/jats:p>","DOI":"10.3389\/fphar.2024.1403988","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:12:52Z","timestamp":1721797972000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Liangxia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1365-2044.2010.06509.x","article-title":"Patient safety incidents involving neuromuscular blockade: analysis of the UK national reporting and learning system data from 2006 to 2008","volume":"65","author":"Arnot-Smith","year":"2010","journal-title":"Anaesthesia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2222.2008.03171.x","article-title":"On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective","volume":"39","author":"Baldo","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0750-7658(05)81017-2","article-title":"Drugs responsible for anaphylactoid reactions in anaesthesia in the United Kingdom","volume":"12","author":"Clarke","year":"1993","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"B6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.redar.2017.12.009","article-title":"Kounys syndrome after rocuronium administration","volume":"65","author":"Del Val Villanueva","year":"2018","journal-title":"Rev. Esp. Anestesiol. Reanim. Engl. Ed."},{"key":"B7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12948-018-0094-7","article-title":"Focus on the agents most frequently responsible for perioperative anaphylaxis","volume":"16","author":"Di Leo","year":"2018","journal-title":"Clin. Mol. Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1399-6576.1994.tb04020.x","article-title":"The agreement between adductor pollicis mechanomyogram and first dorsal interosseous electromyogram. A pharmacodynamic study of rocuronium and vecuronium","volume":"38","author":"Engbaek","year":"1994","journal-title":"Acta Anaesthesiol. Scand."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.ijcard.2008.05.052","article-title":"Rocuronium-induced coronary vasospasm--Kounis syndrome","volume":"137","author":"Fagley","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/s0750-7658(05)81016-0","article-title":"The incidence and clinical features of anaphylactic reactions during anesthesia in Australia","volume":"12","author":"Fisher","year":"1993","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"B11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/bja\/56.6.599","article-title":"Use of atracurium in caesarean section","volume":"56","author":"Flynn","year":"1984","journal-title":"Br. J. Anaesth."},{"key":"B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2044.1985.tb10785.x","article-title":"Anaphylactoid reactions during anaesthesia. Seven years\u2019 experience of intradermal testing","volume":"40","author":"Galletly","year":"1985","journal-title":"Anaesthesia"},{"key":"B14","first-page":"207","article-title":"Pharmacologic induction of fetal immobilization for prenatal diagnostic-therapeutic procedures","volume":"47","author":"Greco","year":"1995","journal-title":"Minerva Ginecol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1365-2044.1997.235-az0367.x","article-title":"Incidence of intra-operative bradycardia. Comparison of atracurium and vecuronium in gynaecological surgery","volume":"52","author":"Hameedullah","year":"1997","journal-title":"Anaesthesia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1046\/j.1365-2044.1999.01076.x","article-title":"A comparison of the effect of rocuronium and vecuronium on heart rate during gynaecological laparoscopy","volume":"54","author":"Harvey","year":"1999","journal-title":"Anaesthesia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1034\/j.1399-6576.2000.440702.x","article-title":"Anaphylactic reactions during induction of anaesthesia using rocuronium for muscle relaxation: a report including 3 cases","volume":"44","author":"Heier","year":"2000","journal-title":"Acta Anaesthesiol. Scand."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1213\/00000539-198867110-00012","article-title":"Combined H1 and H2 receptor blockade attenuates the cardiovascular effects of high-dose atracurium for rapid sequence endotracheal intubation","volume":"67","author":"Hosking","year":"1988","journal-title":"Anesth. Analg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4097\/kjae.2010.58.4.391","article-title":"Anaphylaxis with angioedema by rocuronium during induction of general anesthesia -A case report","volume":"58","author":"Jeong","year":"2010","journal-title":"Korean J. Anesthesiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"989032","DOI":"10.3389\/fphar.2022.989032","article-title":"Post-marketing safety of immunomodulatory drugs in multiple myeloma: a pharmacovigilance investigation based on the FDA adverse event reporting system","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/bja\/62.6.590","article-title":"Atracurium--a post-marketing surveillance study: methods and U.S. experience","volume":"62","author":"Jick","year":"1989","journal-title":"Br. J. Anaesth."},{"key":"B22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4097\/kjae.2016.69.5.453","article-title":"Effective doses of cisatracurium in the adult and the elderly","volume":"69","author":"Kim","year":"2016","journal-title":"Korean J. Anesthesiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0750-7658(05)81015-9","article-title":"Drugs and other agents involved in anaphylactic shock occurring during anaesthesia. A French multicenter epidemiological inquiry","volume":"12","author":"Laxenaire","year":"1993","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.bja.2017.11.106","article-title":"Effects of avoidance or use of neuromuscular blocking agents on outcomes in tracheal intubation: a Cochrane systematic review","volume":"120","author":"Lundstr\u00f8m","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.4155\/fmc.13.164","article-title":"Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents","volume":"5","author":"Macartney","year":"2013","journal-title":"Future Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/aln.0000000000000674","article-title":"Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications","volume":"122","author":"Mclean","year":"2015","journal-title":"Anesthesiology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00000542-200309000-00007","article-title":"Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000","volume":"99","author":"Mertes","year":"2003","journal-title":"Anesthesiology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1097\/ccm.0000000000002027","article-title":"Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient","volume":"44","author":"Murray","year":"2016","journal-title":"Crit. Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/00000542-200201000-00035","article-title":"Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist","volume":"96","author":"Naguib","year":"2002","journal-title":"Anesthesiology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1365-2044.1986.tb12921.x","article-title":"Bronchospasm following the use of vecuronium","volume":"41","author":"O\u2019callaghan","year":"1986","journal-title":"Anaesthesia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/all.13456","article-title":"Neuromuscular blocking agents induced anaphylaxis: results and trends of a French pharmacovigilance survey from 2000 to 2012","volume":"73","author":"Petitpain","year":"2018","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/ph15050645","article-title":"Liver injury with nintedanib: a pharmacovigilance-pharmacokinetic appraisal","volume":"15","author":"Raschi","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/all.12426","article-title":"Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis","volume":"69","author":"Reitter","year":"2014","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/bja\/86.5.678","article-title":"Rocuronium: high risk for anaphylaxis?","volume":"86","author":"Rose","year":"2001","journal-title":"Br. J. Anaesth."},{"key":"B35","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/bja\/aes506","article-title":"Anaphylaxis to neuromuscular blocking drugs: incidence and cross-reactivity in Western Australia from 2002 to 2011","volume":"110","author":"Sadleir","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"B36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/bja\/57.6.550","article-title":"Atracurium: clinical strategies for preventing histamine release and attenuating the haemodynamic response","volume":"57","author":"Scott","year":"1985","journal-title":"Br. J. Anaesth."},{"key":"B37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0976-500x.162004","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"Singh","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/aln.0000000000004379","article-title":"2023 American society of anesthesiologists practice guidelines for monitoring and antagonism of neuromuscular blockade: a report by the American society of anesthesiologists task force on neuromuscular blockade","volume":"138","author":"Thilen","year":"2023","journal-title":"Anesthesiology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/jpm12091538","article-title":"Neuromuscular blockade in the pre- and COVID-19 ARDS patients","volume":"12","author":"Tsolaki","year":"2022","journal-title":"J. Pers. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4103\/ijciis.Ijciis_35_16","article-title":"The Incidence of hypotension with continuous infusion atracurium compared to cisatracurium in the Intensive Care Unit","volume":"7","author":"Vanderweide","year":"2017","journal-title":"Int. J. Crit. Illn. Inj. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e25516","DOI":"10.1097\/md.0000000000025516","article-title":"Serious bronchospasm induced by cisatracurium besylate: a case report","volume":"100","author":"Wang","year":"2021","journal-title":"Med. Baltim."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1249845","DOI":"10.3389\/fphar.2023.1249845","article-title":"Epirubicin and gait apraxia: a real-world data analysis of the FDA adverse event reporting system database","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B43","first-page":"522","article-title":"Incidence of UK reactions involving rocuronium may simply reflect market use","volume":"87","author":"Watkins","year":"2001","journal-title":"Br. J. Anaesth."},{"key":"B44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2044.1985.tb10733.x","article-title":"Severe bronchospasm following the use of atracurium in children","volume":"40","author":"Woods","year":"1985","journal-title":"Anaesthesia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"977582","DOI":"10.3389\/fphar.2022.977582","article-title":"Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: based on food and drug administration adverse event report system database","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1039867","DOI":"10.3389\/fphar.2022.1039867","article-title":"Pharmacovigilance of triazole antifungal agents: analysis of the FDA adverse event reporting system (FAERS) database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403988\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T05:12:57Z","timestamp":1721797977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1403988\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":46,"alternative-id":["10.3389\/fphar.2024.1403988"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1403988","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"article-number":"1403988"}}